Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial
The Anti-Amyloid Treatment in Asymptomatic Alzheimer's study was among the first and largest studies to include biomarker disclosure in a population without cognitive impairment. Routine psychological assessment provided a novel assessment of the impact of disclosure in this sample. Learning an elevated brain amyloid result through a protocolized approach was not associated with suicidal thoughts or behaviors compared to a matched cohort who learned they did not have elevated brain amyloid. Future research will be needed to ensure similar safety in more real-world settings.
Authors
- Reisa Anne Sperling (ORCID: https://orcid.org/0000-0003-1535-6133)
- Karen C. Holdridge
- Jason Karlawish (ORCID: https://orcid.org/0000-0002-6880-2865)
- Charlene Flournoy
- Paul S. S Aisen (ORCID: https://orcid.org/0000-0002-2896-5838)
- David L. Sultzer
- Joshua D. Grill (ORCID: https://orcid.org/0000-0002-4215-7589)
- Jeffrey Murray Burns (ORCID: https://orcid.org/0000-0001-7609-8954)
- Rema Raman (ORCID: https://orcid.org/0000-0002-4096-6390)
- Aimee Pierce (ORCID: https://orcid.org/0000-0002-9423-366X)
- Karin Ernström (ORCID: https://orcid.org/0009-0008-2067-8632)
- Paul B. Rosenberg (ORCID: https://orcid.org/0000-0002-5659-160X)
- Michele Mancini (ORCID: https://orcid.org/0000-0003-0845-2813)
- Amanda Smith
Institutions
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Autism Research Institute (US)
- Harvard University (US)
- Johns Hopkins University (US)
- University of Kansas (US)
- Oregon Health & Science University (US)
- Eli Lilly (United States) (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/alz.14623
- Citations
- 5
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 6.97
Funders
- Alzheimer's Association
- Eli Lilly and Company
- GHR Foundation
- National Institute on Aging